Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Natera Inc's Business Segments
Natera Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 753
Regions Reported
3
Revenue Share by Reportable Segment - Q2 FY2026
- Reportable100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 753 | 100% |
Revenue Share by Region - Q2 FY2026
- EMEA1.2%
- Americas, Excluding United States0.3%
- Asia Pacific and Other0.3%
Revenue by Geographic Region - Q2 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| EMEA | $ 9 | 1.2% |
| Americas, Excluding United States | $ 2 | 0.3% |
| Asia Pacific and Other | $ 2 | 0.3% |
Revenue by Product & Service Category - Q2 FY2026
- Product99.4%
- Licensing and other0.6%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 748 | 99.4% |
| Licensing and other | $ 5 | 0.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Natera Inc
Natera Inc is a multinational healthcare company that specializes in genetic testing and diagnostic solutions. Founded in 2003, the company is headquartered in San Carlos, California, but has operations across the United States, Europe, and Asia. Natera is publicly traded on the NASDAQ and currently employs over 1,200 people worldwide. The company's mission is to improve the lives of millions of patients and families by providing them with advanced genetic testing and diagnostics.
Natera offers a range of genetic testing solutions that enable healthcare providers to diagnose, monitor, and manage various health conditions. The company specializes in non-invasive prenatal testing (NIPT), which uses cell-free DNA (cfDNA) technology to detect certain genetic abnormalities in the fetus without the need for invasive procedures. The company's flagship product, Panorama, is a market-leading NIPT test that screens for common chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome.
In addition to NIPT, Natera provides a range of other genetic testing solutions for reproductive health, oncology, and organ transplantation. The company's products include tests for hereditary cancer risk assessment, inherited cardiovascular conditions, and reproductive genetics. Natera also offers a liquid biopsy test, Signatera, that detects the presence of circulating tumor DNA in cancer patients, providing insight into disease progression and treatment efficacy.
Beyond its focus on genetic testing and diagnostics, Natera is also engaged in research and development activities aimed at advancing the field of genomics. The company has partnerships with leading academic and research institutions and invests heavily in innovation and technology development. Natera has a portfolio of more than 300 issued and pending patents and has won numerous awards for its pioneering work in genomics.
In recent years, Natera has experienced significant growth, driven by rising demand for genetic testing and a growing trend towards personalized medicine. The company's financial performance has been strong, with revenues of $355.6 million in 2020, up from $302.3 million in 2019. Natera is committed to continued growth and expansion across its key markets, with a focus on advancing its technology, expanding its product offerings, and increasing market share.
Natera offers a range of genetic testing solutions that enable healthcare providers to diagnose, monitor, and manage various health conditions. The company specializes in non-invasive prenatal testing (NIPT), which uses cell-free DNA (cfDNA) technology to detect certain genetic abnormalities in the fetus without the need for invasive procedures. The company's flagship product, Panorama, is a market-leading NIPT test that screens for common chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome.
In addition to NIPT, Natera provides a range of other genetic testing solutions for reproductive health, oncology, and organ transplantation. The company's products include tests for hereditary cancer risk assessment, inherited cardiovascular conditions, and reproductive genetics. Natera also offers a liquid biopsy test, Signatera, that detects the presence of circulating tumor DNA in cancer patients, providing insight into disease progression and treatment efficacy.
Beyond its focus on genetic testing and diagnostics, Natera is also engaged in research and development activities aimed at advancing the field of genomics. The company has partnerships with leading academic and research institutions and invests heavily in innovation and technology development. Natera has a portfolio of more than 300 issued and pending patents and has won numerous awards for its pioneering work in genomics.
In recent years, Natera has experienced significant growth, driven by rising demand for genetic testing and a growing trend towards personalized medicine. The company's financial performance has been strong, with revenues of $355.6 million in 2020, up from $302.3 million in 2019. Natera is committed to continued growth and expansion across its key markets, with a focus on advancing its technology, expanding its product offerings, and increasing market share.
Natera Inc. is a prominent figure in the field of genetic testing and diagnostic services, leveraging cutting-edge technologies to provide extensive solutions aimed at improving health outcomes. The company’s offerings can be grouped into several key segments, notably:
1. Womens Health
The Women’s Health segment encompasses a range of reproductive genetic testing services that serve to empower couples in their family planning and pregnancy-related decisions. Key offerings include:
- Non-Invasive Prenatal Testing (NIPT): This test analyzes cell-free fetal DNA in maternal blood to assess the risk of certain chromosomal conditions, such as Down syndrome. It is praised for its high accuracy and low false-positive rates, allowing expectant parents to make informed choices with greater confidence.
- Preimplantation Genetic Testing (PGT): Offered as part of assisted reproductive technology (ART), this test screens embryos for specific genetic conditions prior to implantation, increasing the likelihood of successful pregnancies and healthy births. It caters to couples with known genetic issues or those undergoing in vitro fertilization (IVF).
- Carrier Screening: Natera provides tests that determine whether individuals carry genetic mutations associated with inherited disorders. This service guides prospective parents in understanding their risk of having children affected by conditions such as cystic fibrosis, spinal muscular atrophy, and sickle cell disease.
Oncology
The Oncology segment focuses on personalized cancer care, delivering advanced testing solutions that assist oncologists in making data-informed treatment decisions and monitoring patient responses. Key products include:
- Signatera: A custom circulating tumor DNA (ctDNA) test designed to detect tumor-specific mutations, enabling the monitoring of residual disease following treatment and early detection of recurrence. This non-invasive approach provides precise insights into a patients unique cancer profile.
- Passthrough: This test identifies chromosomal abnormalities in cancer cells, offering additional information that can be critical in tailoring treatment plans. By understanding the genetic landscape of an individual’s cancer, healthcare providers can select therapies that may be more effective based on the tumors characteristics.
Organ Health
Nateras Organ Health segment aims to support transplant patients through specialized monitoring services. The cornerstone of this segment is:
- Prospera: A non-invasive test for kidney transplant recipients that monitors the presence of donor-derived cell-free DNA to detect organ rejection early. This test allows for timely intervention, potentially improving transplant outcomes. The ability to offer quick and accurate results enhances the management of transplant patient care.
Other Services
In addition to the primary segments, Natera provides a variety of other genetic testing services, including:
- Carrier Screening for Inherited Disorders: Expanding on its offerings by including tests for a broader range of genetic conditions, enabling comprehensive family planning options.
- Pharmacogenomics Testing: This service helps determine how an individuals genetic makeup influences their response to medications, facilitating personalized treatment plans and minimizing adverse drug reactions.
- Genetic Counseling Services: Natera offers access to trained genetic counselors who assist patients in understanding test results, implications for their health, and family planning.
- Clinical Software Solutions: Natera also develops innovative software tools designed to enhance clinical efficiencies, streamline workflows for healthcare providers, and analyze genetic data effectively.
By integrating advanced technologies and comprehensive data analytics, Natera is at the forefront of precision medicine, addressing the multifaceted genetic components that can impact health and wellness. Through these diverse offerings, the company empowers healthcare providers and patients alike in their pursuits of informed health decisions, improved outcomes, and enhanced quality of life.
1. Womens Health
The Women’s Health segment encompasses a range of reproductive genetic testing services that serve to empower couples in their family planning and pregnancy-related decisions. Key offerings include:
- Non-Invasive Prenatal Testing (NIPT): This test analyzes cell-free fetal DNA in maternal blood to assess the risk of certain chromosomal conditions, such as Down syndrome. It is praised for its high accuracy and low false-positive rates, allowing expectant parents to make informed choices with greater confidence.
- Preimplantation Genetic Testing (PGT): Offered as part of assisted reproductive technology (ART), this test screens embryos for specific genetic conditions prior to implantation, increasing the likelihood of successful pregnancies and healthy births. It caters to couples with known genetic issues or those undergoing in vitro fertilization (IVF).
- Carrier Screening: Natera provides tests that determine whether individuals carry genetic mutations associated with inherited disorders. This service guides prospective parents in understanding their risk of having children affected by conditions such as cystic fibrosis, spinal muscular atrophy, and sickle cell disease.
Oncology
The Oncology segment focuses on personalized cancer care, delivering advanced testing solutions that assist oncologists in making data-informed treatment decisions and monitoring patient responses. Key products include:
- Signatera: A custom circulating tumor DNA (ctDNA) test designed to detect tumor-specific mutations, enabling the monitoring of residual disease following treatment and early detection of recurrence. This non-invasive approach provides precise insights into a patients unique cancer profile.
- Passthrough: This test identifies chromosomal abnormalities in cancer cells, offering additional information that can be critical in tailoring treatment plans. By understanding the genetic landscape of an individual’s cancer, healthcare providers can select therapies that may be more effective based on the tumors characteristics.
Organ Health
Nateras Organ Health segment aims to support transplant patients through specialized monitoring services. The cornerstone of this segment is:
- Prospera: A non-invasive test for kidney transplant recipients that monitors the presence of donor-derived cell-free DNA to detect organ rejection early. This test allows for timely intervention, potentially improving transplant outcomes. The ability to offer quick and accurate results enhances the management of transplant patient care.
Other Services
In addition to the primary segments, Natera provides a variety of other genetic testing services, including:
- Carrier Screening for Inherited Disorders: Expanding on its offerings by including tests for a broader range of genetic conditions, enabling comprehensive family planning options.
- Pharmacogenomics Testing: This service helps determine how an individuals genetic makeup influences their response to medications, facilitating personalized treatment plans and minimizing adverse drug reactions.
- Genetic Counseling Services: Natera offers access to trained genetic counselors who assist patients in understanding test results, implications for their health, and family planning.
- Clinical Software Solutions: Natera also develops innovative software tools designed to enhance clinical efficiencies, streamline workflows for healthcare providers, and analyze genetic data effectively.
By integrating advanced technologies and comprehensive data analytics, Natera is at the forefront of precision medicine, addressing the multifaceted genetic components that can impact health and wellness. Through these diverse offerings, the company empowers healthcare providers and patients alike in their pursuits of informed health decisions, improved outcomes, and enhanced quality of life.